Comments on: Will Synta Break A 30 Year Old Record? (Part I) http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/ Biotech stock reviews Sat, 04 Feb 2012 08:55:28 +0000 http://wordpress.org/?v=2.3.1 By: Joe http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-587 Joe Thu, 05 Mar 2009 03:50:09 +0000 http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-587 Another one bites the dust... Elesclomol fails phase III trial http://skincancer.about.com/b/2009/03/01/stunning-disappointment-for-melanoma-drug.htm FYI, five other possibilities in the melanoma market: http://skincancer.about.com/od/treatmentoptions/a/melanoma_trials.htm Great site, thanks for your hard work. Another one bites the dust…

Elesclomol fails phase III trial

http://skincancer.about.com/b/2009/03/01/stunning-disappointment-for-melanoma-drug.htm

FYI, five other possibilities in the melanoma market:

http://skincancer.about.com/od/treatmentoptions/a/melanoma_trials.htm

Great site, thanks for your hard work.

]]> By: Ohad Hammer http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-137 Ohad Hammer Wed, 23 Apr 2008 03:26:16 +0000 http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-137 Antisoma looks very interesting indeed. Strong data. Thanks for bringing it up, Dean. Antisoma looks very interesting indeed. Strong data.
Thanks for bringing it up, Dean.

]]> By: dean http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-136 dean Tue, 22 Apr 2008 14:45:12 +0000 http://www.hammerstockblog.com/will-synta-break-a-30-year-old-record-part-i/#comment-136 Am a medical oncologist who occasionally invests in biotech. Nice article on snta-agree that the phase 2 data not perfect but good (i'm long). Also, nice comments re the multitude of single arm phase 2 studies which are followed by negative phase 3 studies. Another interesting company with randomized phase 2 data is antisoma (i'm also long). Am a medical oncologist who occasionally invests in biotech. Nice article on snta-agree that the phase 2 data not perfect but good (i’m long). Also, nice comments re the multitude of single arm phase 2 studies which are followed by negative phase 3 studies. Another interesting company with randomized phase 2 data is antisoma (i’m also long).

]]>